Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates
08:20am, Thursday, 05'th Feb 2026
Haemonetics (HAE) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.19 per share a year ago.
Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
06:00am, Thursday, 05'th Feb 2026
Financial release and supplemental presentation accessible online BOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal
Allspring Common Stock Fund Q4 2025 Performance Review
09:13am, Wednesday, 28'th Jan 2026
In the fourth quarter, Revolve's stock rose as its revenue met expectations with a 4.4% year-over-year increase. In fiscal second quarter 2026, Haemonetics delivered strong performance, raising guidan
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Thursday, 22'nd Jan 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
07:00am, Wednesday, 21'st Jan 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission (EC) has approved DAWNZERA™ (d
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
10:45am, Thursday, 15'th Jan 2026
Haemonetics' plasma and hemostasis franchises show solid growth potential, but macro headwinds and competition cloud the near-term outlook.
Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12:46pm, Tuesday, 13'th Jan 2026
Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Haemonetics (HAE) is a Strong Growth Stock
10:47am, Monday, 12'th Jan 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
09:00am, Monday, 12'th Jan 2026
$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategi
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
01:48am, Monday, 12'th Jan 2026
/PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP Health Economics Fund has exited Vivasure Medical Limited ("Vivasure" or the "Company"),
Will Haemonetics (HAE) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Friday, 09'th Jan 2026
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Haemonetics Expands Heart Surgery Arsenal With Vivasure Acquisition
08:16am, Friday, 09'th Jan 2026
Haemonetics (HAE) to acquire Vivasure Medical Limited for 100 million euros upfront plus potential milestone payments.
Vivasure Medical Announces Acquisition by Haemonetics Corporation
08:00am, Friday, 09'th Jan 2026
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haem
Haemonetics Acquires Vivasure Medical Limited
06:15am, Friday, 09'th Jan 2026
BOSTON, Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today ann
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026
06:17pm, Wednesday, 07'th Jan 2026
BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, Febru
